The Business Research Company Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout. LONDON, GREATER ...
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Pharmaceutical Technology on MSN5d
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shotNovo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...
Investor's Business Daily on MSN6d
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up ...
The issuer is solely responsible for the content of this announcement.
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.
Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback